⌘K
t
Nuformix plc announced on 5 February 2026 that its Annual Financial Report for the year ended 30 September 2025 and the 2026 Notice of Annual General Meeting (AGM) are being posted to shareholders. The AGM is scheduled for 3 March 2026 at 9:30 a.m.
| Date | 5 Feb 2026 |
| Time | 12:00:00 |
| Category | AGMs and other meetings |
| ID | 8839R |
5 February 2026
Nuformix plc
("Nuformix" or the "Company")
Posting of Annual Report and Notice of Annual General Meeting ("AGM")
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that the Annual Financial Report for the year ended 30 September 2025 (the "Annual Financial Report 2025") and the 2026 Notice of AGM are today being posted to its shareholders.
A full pdf version of the Annual Financial Report 2025 together with the Notice of AGM is available for download from the Investor Information section on the Company's website: www.nuformix.com.
The Annual General Meeting will be held at the offices of Arch Law, level 2, Huckletree, 8 Bishopsgate, London, EC2N 4BQ at 9.30 a.m. on 3 March 2026.
Enquiries:
|
Nuformix plc |
|
|
Dr Dan Gooding, Executive Director
|
Via IFC Advisory |
|
CMC Markets |
|
|
Douglas Crippen |
+44 (0) 20 3003 8632 |
|
|
|
|
IFC Advisory Limited |
|
|
Tim Metcalfe Zach Cohen |
+44 (0) 20 3934 6632 |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
For more information, please visit www.nuformix.com.